ArticlePostepy dermatologii i alergologii2026
A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia.
Article in Postepy dermatologii i alergologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Long-term real-life data on the efficacy of dupilumab in atopic dermatitis (AD) patients, especially within the paediatric population, are limited. Aim: We aimed to evaluate in real life the effectiveness and safety of dupilumab in the treatment of adults and paediatric patients (6-17 years) with a special focus on the (hyper)eosinophilia trend during treatment. Material and methods: A monocentric retrospective study was conducted at the Department of Dermatology, Venereology, and Allergology in Gdansk, Poland. Results: A total of 70 patients were included, comprising 44 adults and 26 paediatric patients. In paediatric patients, Eczema Area and Severity Index (EASI) decreased by 86.65%, pruritus (P-NRS) by 72.40%, sleep disturbances (SD-NRS) by 73.44%, and Children's Dermatology Life Quality Index (cDLQI) by 76.82% at week (W) 52. In adults, EASI decreased by 95.66%, P-NRS by 79.66%, SD-NRS by 92.12%, and Dermatology Life Quality Index (DLQI) by 87.54% at W104. Among the paediatric patients, 17 experienced (hyper)eosinophilia at baseline (17/25, 68.0%), and 22 experienced (hyper)eosinophilia during the treatment period (22/26, 84.62%). Among adults, 24 experienced (hyper)eosinophilia at baseline (24/44, 54.55%), and 35 experienced (hyper)eosinophilia during the treatment period (35/44, 79.55%). No one discontinued treatment due to hypereosinophilia. Conclusions: Our results demonstrate that dupilumab is an effective and safe treatment for AD in both paediatric and adult populations in real-life settings, with significant and lasting improvements in disease severity and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.